Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 4 | Lipids in Health and Disease

Fig. 4

From: Estimating the effect of inclisiran on hypercholesterolemia and primary prevention of cardiovascular disease: the NHANES 1999–2018 study

Fig. 4

Central illustration. Based on the inclusion and exclusion criteria of the ORION-10 and ORION-11 trials, 5 million ASCVD patients and 2.7 million ASCVD-risk equivalent individuals were identified from a population of 261 million Americans. Among the ASCVD patients, 3.5 million (70.2%) could achieve LDL-C reductions of ≥ 50%, 4.6 million (91.3%) could reach LDL-C levels below 70 mg/dL, and 3.8 million (75%) could reach levels below 55 mg/dL with inclisiran treatment. In the ASCVD-risk equivalent population, inclisiran could potentially prevent 202,353 (7.6%) CVD events, including 138,084 (5.2%) CHD events, 37,351 (1.4%) strokes, and 23,894 (0.9%) CHF events over a 10-year period. Note Each small white man icon approximately represents 330,000 Americans. *ORION-11 criteria apply only to ASCVD-risk equivalent subjects. Abbreviations ASCVD, atherosclerotic cardiovascular disease; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; CHD, coronary heart disease; CHF, congestive heart failure

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X